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ABSTRACT
With the incidence of Alzheimer’s disease (AD) growing worldwide and in Canada along
with the growing economic and social burdens, the need for more effective therapies becomes of
great importance. Since the discovery of AD, a number of proposed theories have arisen to
explain the pathophysiology including the i) cholinergic theory, ii) oxidative stress pathways,
and iii) metal ion imbalance. The major class of drug therapies to treat AD are cholinesterase
inhibitors; however, the “one drug, one target” approach has not proven fruitful and generally
becomes ineffective in later stages of disease progression. In this project, we synthesized a
library of 1,2,3,4-tetrahydroacridine derivatives (10a-d, 11a-e, 12a-e, and 13a-f) as potential
agents to target the cholinergic and oxidative stress pathways of AD. Chapter I provides
background information on the role of AChE and BuChE enzymes in AD. Furthermore, this
chapter describes the neurotoxicity of reactive oxygen species (ROS) and metals in AD. Chapter
II provides a summary of project hypothesis and rationale. Chapter III describes the synthetic
details regarding the synthesis of target small molecules. It further describes the principles
involved in carrying out biological evaluation such as AChE and BuChE inhibition, antioxidant
properties via DPPH stable radical scavenging, iron chelation capacity using ferrozine and in
vitro cell viability data in neuroblastoma cells. Chapter IV describes the SAR details on ChE
inhibition, antioxidant activities, iron chelation and cell viability profiles and molecular
modeling details. A brief conclusion and future directions are included in Chapter V and the final
section, Chapter VI provides experimental details for synthetic chemistry including analytical
data of synthesized compounds and protocols for biological evaluations. This study identified
novel tetrahydroacridine derivatives with nanomolar inhibition of both human AChE and human
BuChE enzymes that were more potent relative to the reference agent tacrine. Compound 10d
iv
[N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine] was identified as a potent inhibitor
of BuChE (IC50 = 24.0 nM) and compound 13c [6-chloro-N-(pyridine-2-ylmethyl)-1,2,3,4-
tetrahydroacridin-9-amine] was identified as a potent inhibitor of AChE (IC50 = 95.0 nM) with
good inhibition of BuChE (IC50 = 1.61 µM) whereas compound 11e [6-chloro-N-(3,4-
dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine] was identified with an optimum
combination of dual AChE and BuChE inhibition (AChE IC50 = 0.9 µM; BuChE IC50= 1.4 µM).
In conclusion, our studies provide new insight into the design and development of novel
tetrahydroacridine derivatives to target multiple pathological routes of AD.
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1CHAPTER I
Introduction
1.1 The History of Alzheimer’s Disease
In 1907, Alois Alzheimer diagnosed a patient for the first time with a type of dementia
which would later be identified as Alzheimer’s disease (AD).1 Symptoms including memory loss
and cognitive dysfunction were typified as hallmarks of AD and were found to affect the aging
population.1,2 Anatomical hallmarks include the presence of senile plaques and neurofibrillary
tangles. The reason for the decrease in memory and cognitive ability for those living with AD is
due to the neurodegenerative nature of the disease. The resulting affect of AD is a decrease in
brain mass, affecting cholinergic neuron-dense areas of the central nervous system (CNS) such
as the nucleus basalis of Meynert and the hippocampus, areas of the brain which have roles in
memory and cognition.3,4 Ultimately, after disease progression, patients will develop issues with
speech, recollection of past events, and difficulties with concentration.1,5
Since its discovery, AD has had an increasing socio-economic burden and as of 2011
approximately 36 million individuals worldwide are living with AD.6 By 2030, this number is
expected to increase to almost 66 million. In the United States alone, caregivers, such as family
members and friends, contribute nearly 17 billion hours of unpaid work valued at almost $200
billion, and costs of $200 billion for healthcare providers, long-term care and hospices already
strain the American healthcare system in addition to the 500 000 Canadians with AD.7 It has
been a major challenge to determine the initial cause of AD as it is a multifaceted disorder. A
number of hypotheses have been posited to resolve the etiology of AD with research being done
to determine the major driving forces for the disease.
21.2 The Cholinergic Hypothesis
Alzheimer’s disease primarily results in the neurodegeneration of cholinergic neurons in
the CNS resulting in decreased neuronal cell signalling, an important process in basic human
physiology. During AD, there is a decrease in the levels of choline acetyltransferase (ChAT), the
enzyme responsible for catalysis of acetylcholine (ACh, Fig. 1) formation, resulting in a decrease
in ACh levels in the CNS.8 As one of the crucial neurotransmitters, ACh is used by cholinergic
neurons to communicate with other neurons via propagation of a neural impulse. ACh is released
as a chemical neurotransmitter by a pre-synaptic neuron into a region called the synaptic cleft.
The ACh will traverse this region and bind to cholinergic receptors on the post-synaptic neuron,
thus propagating the neuronal signal. Cholinesterases will further deplete the level of ACh thus
exacerbating the condition and further promoting AD pathology.
Figure 1: Chemical structure of the neurotransmitter acetylcholine (ACh)
1.2.1 The Cholinesterases
Acetylcholinesterase (AChE) (EC 3.1.1.7) and butyrylcholinesterase (BuChE) (EC
3.1.1.8) are both responsible for enzymatically hydrolyzing ACh into its inactive metabolites,
acetate and choline (Fig. 2).9
3Figure 2: Enzymatic mechanism of acetylcholine hydrolysis by AChE (Glu334, His447, Ser 203) and BuChE
(Glu325, His 438, Ser198)
Under normal physiological conditions AChE is the major enzyme that is known to
recycle or remove excess ACh in the CNS. In early stages of AD, AChE is the primary ACh
degrading enzyme; however, during disease progression there is a shift in the ratio between
AChE and BuChE where BuChE becomes the primary ACh hydrolyzing enzyme.10 Figure 2
gives the schematics of ACh hydrolysis by ChEs. Different regions of AChE exist in which its
primary substrate, ACh, can interact. The AChE active site gorge is located 20 Å away from the
entrance and is comprised of a catalytic triad consisting of residues serine (Ser) 203, glutamate
(Glu) 334 and histidine (His) 447.11,12 AChE depends on key hydrophobic residues to stabilize
ACh once it has entered the active site allowing for its hydrolysis. These residues include
phenylalanine (Phe) 338, and the cationic-π site residue, tryptophan (Trp) 86.11,13 There also
exists an acyl pocket comprised of Phe295 and Phe297, which stabilize the acetyl moiety of
ACh. One particular region is the peripheral anionic site (PAS), with key residues including Trp
286, tyrosine (Tyr) 341, and aspartate (Asp) 72, which aid in directing ACh to the active site
4entrance.11,12 The PAS has been implicated in promoting the generation of beta amyloid (Aβ)
plaques resulting in further neuronal damage.14-16 It has also been found that PAS-specific
binding by certain drug compounds can inhibit the formation of these plaques.17 Like AChE,
BuChE also has an active site with a catalytic triad comprised of Ser198, Glu325 and His438 as
well as Trp82 and Phe329 as hydrophobic stabilizers of ACh.11,18 However, BuChE does not
have a PAS, and its acyl pocket is lined by aliphatic residues leucine (Leu) 286 and valine (Val)
288, which are smaller than the Phe residues in AChEs acyl pocket.18The smaller residues, along
BuChEs active site contribute to its approximately 200 Å3 greater active site compared to AChE,
allowing BuChE to bind to a greater pool of substrates larger than ACh.18,19 While the role of
AChE has been well-documented, the exact function of BuChE in humans has yet to be
discerned.
Figure 3: Active sites of hAChE (PDB:1B41) and hBuChE (PDB:1P0I), red: catalytic site, blue: cationic-π site,
yellow: acyl pocket, green: gorge entry/PAS
5Cholinesterase inhibitors (ChEI) represent the major class of drug treatments used in AD
therapy. Some known ChEIs include donepezil (Aricept®), rivastigmine (Exelon®), galantamine
(Reminyl®), and tacrine (Cognex®) (Fig. 4). Each treatment varies in the selectivity for AChE
versus BuChE, and its effectiveness at various stages in AD progression, with some being more
effective in early AD and others in intermediate stages.
Figure 4: Chemical structures of past and current therapies used in AD treatment
1.2.2 Summary
The cholinergic hypothesis aims to make the connection between the decrease in
cognitive and memory functions in AD patients with the reductions in ACh levels. The decreased
levels of ChAT resulting in slower production of ACh coupled with the hydrolyzing activity of
AChE and BuChE account for the decrease in ACh in cholinergic-dense regions of the CNS,
6which are responsible for reduction in cognition and memory. Development of ChEIs have
shown improvement with respect to the aforementioned symptoms; however, the exact cause and
driving factors in AD are yet to be determined, and suggests that the cholinergic hypothesis is
merely one facet in explaining this complex disease.
1.3 The Effect of Metals in AD
The multifaceted nature of AD is a major challenge in determining primary factors that
result in the initiation of AD. It has been shown that certain metal ions have had a significant role
in the progression of the disease by promoting neuronal cell damage via oxidative stress
pathways.20,21 Increased levels of iron (III) (Fe3+), copper (II) (Cu2+) and zinc (II) (Zn2+) have
been shown to promote the generation of reactive oxygen species (ROS) either through direct or
indirect redox activity. 22 There is a marked increase in oxidative damage found in the CNS of
AD patients due to the generation and increasing levels of ROS.23-25 The connection between
metal ion concentration and ROS generation makes these specific metals key pathogenic factors
in AD progression as oxidative stress has a significant role in neuronal damage and cell
death.22,26,27 As with normal age progression, there is a natural increase in the concentrations of
these metals; however, patients with AD have been found to have significantly higher
concentrations in the CNS compared to age-matched controls.28-34 Firstly, Fe3+ can promote
increased translation of amyloid precursor protein (APP) by preventing iron response proteins
from inhibiting an iron response element. The increase in APP results in an increase in Aβ
peptides being formed, including Aβ1-40 and Aβ1-42. These peptides can go on to form oligomers
that aggregate into fibrils, fibers, filaments, and consequently will form into senile plaques, one
of the hallmarks of AD. Due to Aβ’s high affinity for the aforementioned metal ions, they will
continue to interact with senile plaques to generate ROS. It has been demonstrated that increased
7Zn2+ as well as Cu2+ and Fe3+ promote increased Aβ aggregation characteristic of AD.35-38 It is
also suggested there are binding sites located on Aβ selective for both Cu2+ and Zn2+ that
promote Aβ-aggregation.28,39 Chelation of these ions inhibit the formation of senile plaques by
solubilising the Aβ peptides.40 All three metals are generally found in higher concentrations
within Aβ deposits. Through redox reactions, peroxide is generated from the interaction of
redox-active Fe3+ or Cu2+ and Aβ1-40/1-42, in which peroxide undergoes further redox reactions via
Fenton chemistry and Haber-Weiss reactions to generate free radicals (Fig. 5).
Figure 5: Reaction scheme of ROS generation through metal reduction via Fenton chemistry and Haber-Weiss
reactions
1.4 The Effect of ROS in AD
As mentioned, the increase in metal ion concentration results in increased ROS
generation, which go on to induce the inflammatory response and cellular damage in the CNS.41-
43 Major ROS include that of peroxide (H2O2), superoxide (O2●-), and hydroxy radical (OH●).
Specifically, these ROS target lipids, protein structures, and induce DNA damage, all integral in
cell function and structure.44 Unfortunately in AD, the ROS clearance mechanisms in key
8regions of the CNS are reduced, including a reduction in levels of superoxide dismutase (SOD)
and glutathione peroxidises.45 The interaction between Aβ and Cu2+ resulting in the reduction of
Cu2+ into Cu1+ and generation of neurotoxic peroxide, is markedly reduced in the presence of a
copper chelator.39 Several effective antioxidants function by stabilizing existing free radicals
generally through different resonance structures, thus making them far less reactive than other
ROS (Fig. 6). This exchanges the highly reactive and inflammatory hydroxy free radical (OH●)
with a less reactive molecule that can be cleared from the body without producing significant
cellular damage or inflammation. ROS generated in vitro due to Aβ have been shown to be
removed by enzymatic and chemical ROS scavengers.46-47 Effective antioxidants, which have
demonstrated neuroprotective effects in in vivo AD animal models include resveratrol and
curcumin (Fig. 7).45,48-51 However, these antioxidants demonstrate instability in aqueous
environments and/or poor bioavailability and may suggest why they have not been effective in
treating patients with AD.52-56 Potent metal chelators include compounds possessing nitrogen-
substituted functional groups that can chelate with metal ions forming a stable 5- or 6-membered
ring systems (Fig. 7).
Figure 6: Mechanism of free-radical scavenging by antioxidants through resonance stabilization
9Figure 7: Structures of common antioxidants, resveratrol and curcumin, and metal chelator, clioquinol
1.4.1 Summary
The direct interaction between Cu2+ or Zn2+, and Aβ1-40/1-42 peptides promotes its
aggregation into larger senile plaques. Additionally, Fe3+ promotes further expression of the APP
which ultimately results in increased Aβ peptide formation. The following interactions between
the senile plaques and redox-active Cu2+ and Fe3+ results in the generation of ROS, through
Haber-Weiss reactions and Fenton chemistry, that go on to induce oxidative damage in the CNS.
The introduction of metal chelators can inhibit the formation of these plaques and ROS.
Furthermore, introduction of anti-oxidants are effective means of scavenging free radicals and
other ROS, to reduce oxidative damage associated with AD.
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1.5 Tacrine and Alzheimer’s disease treatments
Tacrine is a potent (AChE IC50 = 190-230 nM, BuChE IC50= 40-45 nM) selective dual-
ChEI and was the first agent approved by the Food and Drug Administration (FDA) to treat AD,
as Cognex (Pfizer and Warner-Lambert, New York, NY).57 Tacrine’s planar orientation allows it
to bind closer to Trp86 in the active site of AChE preventing the stabilisation and hydrolysis of
ACh. Currently, tacrine is no longer used to treat AD as it is associated with hepatotoxicity;
however it remains as a reference compound and scaffold to develop potent ChEIs.  Several
research groups have synthesized novel tacrine derivatives and hybrids with potent ChEI (Fig.
8).58-60
Figure 8: Chemical structure and ChE IC50 values of various tacrine derivatives
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1.6 Chapter I Conclusion
In this chapter we examined the significant socioeconomic impact that Alzheimer’s
disease inflicts on national healthcare systems, on patients, and patient caregivers. With billions
of dollars being spent in North America, there is a mandate for a better understanding of the
disease and how to control it. Several hypotheses have arisen since the discovery of AD to better
understand its pathophysiology including: i) the cholinergic hypothesis, ii) abnormalities in metal
concentrations in the CNS, and iii) the oxidative stress pathway as shown in Figure 9 (Fig. 9).
The first of these hypotheses, the cholinergic hypothesis, describes the significance of decreased
ACh levels in the CNS leading to the hallmark symptoms of AD, including cognitive impairment
and memory loss. The decrease of ACh levels is also made worse by the activity of ChE
enzymes that further deplete ACh via hydrolysis. Next was the deregulation of metal ion
concentrations in the brain whereby increased levels of iron, copper, and zinc ions contribute to
the increased expression of Aβ peptides and interaction with senile plaques to generate ROS.
Finally, these ROS promote oxidative stress where neuronal cell membranes and structures are
damaged or destroyed promoting further AD progression. A major class of drug therapies known
as cholinesterase inhibitors have been developed in order to treat AD with tacrine being the first
FDA-approved ChEI and has become a major scaffold for developing novel drug therapies to
treat AD.
12
Figure 9: Outline of Alzheimer’s disease pathology, major hallmarks and symptoms (red), and treatments (blue)
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CHAPTER II
Hypothesis and Design Rationale
2.1 Template Design
Figure 10: THA template design as dual-ChEI with antioxidant and chelating properties
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The goal of this project was to develop a library of tricyclic derivatives based on a
1,2,3,4-tetrahydroacridine (THA) ring scaffold as dual-ChEI. Furthermore, substituents at C-9
position were varied to incorporate antioxidant and metal-chelating pharmacophores to target the
oxidative stress pathway in AD (Fig. 10)
2.2 Target Derivatives
The fundamental goal of the project was to generate a library of THA derivatives and
vary their electronic and steric parameters at C-6, C-7, and C-9 positions in order to evaluate
their ability to: i) inhibit AChE and BuChE enzymes, and ii) exhibit antioxidant and metal
chelating properties. The general synthetic route to obtain the library of target compounds is
shown in Figure 11.
Figure 11: General overview of synthetic routes and functional groups of target compounds
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CHAPTER III
Chemistry and Biological Evaluation
3.1 Computational Chemistry
Initially, the binding interaction of the THA derivative tacrine was investigated using the
molecular modeling software Discovery Studio from Accelrys Inc. The known crystallographic
coordinates of tacrine bound to both AChE and BuChE were studied to determine key polar and
nonpolar interactions. Furthermore, THA derivatives containing various substituents and
pharmacophores at C-6, C-7 and C-9 were assembled using the build fragment protocol in
Discovery Studio. Energy minimized structures were docked in the active sites of both AChE
and BuChE enzymes and their interaction energies were analyzed and ranked using a scoring
function (Libdock Score) present in the docking module LibDock. Furthermore, critical
parameters such as hydrogen bonding interactions, van der Waals interaction and electrostatic
interactions were thoroughly investigated and compared with tacrine. Substituents were
optimized further based on initial SAR screen for ChE inhibition to obtain better ChE inhibition.
3.2 Synthetic Chemistry
Synthetic schemes were optimized involving three to four steps to obtain target
molecules. Post-synthesis purification was done by traditional work-ups and flash
chromatography.
The THA derivatives with various C-6, C-7 and C-9 substituents were synthesised as per
Scheme 1. Initially, nitro-substituted benzoic acid (1, 2, or 3) was reduced to an amine
derivative (4, 5, or 6) in the presence of tin (II) chloride (SnCl2) or by palladium (Pd/C) and
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hydrazine under reflux (Reaction  a and b, Scheme 1 and 2, Fig. 11).61-62 The intermediate (7, 8,
or 9) was synthesized by coupling (4, 5, or 6) with cyclohexanone in presence of phosphorous
oxychloride (POCl3) under reflux (Reaction c, Scheme 1 - 3).63 Consequently, a nucleophilic
substitution reaction with various benzylamine and picolylamine derivatives provided C-9
substituted tacrine derivatives (Reaction d, Scheme 1, 2 and 3).64
3.2.1 Synthetic Scheme to Prepare THA Derivatives (10 – 13)
Reagents and Conditions. a: tin(II)chloride, EtOH, reflux at 75ºC 1h; b: Pd/C, hydrazine, EtOH, reflux at 80ºC 1.5
h; c: cyclohexanone, POCl3, reflux at 120ºC 2.5 h; d: i) benzylamines, butanol, NaI, reflux 150ºC 4.5 h ii)benzylamines, phenol, NaI, reflux 180ºC 3 h
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Reagents and Conditions. a: tin(II)chloride, EtOH, reflux at 75ºC 1h; c: cyclohexanone, POCl3, reflux at 120ºC 2.5h; d: i) benzylamines, butanol, NaI, reflux 150ºC 4.5 h ii) benzylamines, phenol, NaI, reflux 180ºC 3 h
Reagents and Cinditions. d: picolylamines, butanol, NaI, reflux 150ºC 4.5 h
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3.2.1. Intermediate Product Synthesis – Reaction a
The intermediate compounds 2-aminobenzoic acid and its chloro derivatives (1, 2, 3)
were prepared via reduction of the C-2 nitro group into a primary amine (Fig. 12)
Figure 12: Reaction mechanism showing reduction of 2-nitrobenzoic acid into 2-aminobenzoic acid in presence of
tin(II)chloride
The chloro- and non-chloro-nitrobenzoic acid starting material (1, 2, or 3, Scheme 1 and
2) was reduced in the presence of tin(II)chloride to convert the nitro group into an amine.
Although Reaction b produces superior yield of the unchlorinated aminobenzoic acid
intermediate, the use of a Pd/C-hydrazine reaction results in the displacement of the chlorine
group from chloro-nitrobenzoic acid.
The chloro and nonchloro 2-nitrobenzoic acid starting materials (1, 2, 3, Fig. 12) were
reacted in the presence of tin(II)chloride, which would dissociate to give low valent tin species
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that would go on to reduce the nitro group (NO2), to amine (NH2) in presence of ethanol as a
solvent thus producing chloro and non-chloro-aminobenzoic acid products (4, 5, or 6)
Figure 13: Overview of a brine-wash reaction workup
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3.2.1.2 Intermediate Product Synthesis– Reaction b
The intermediate compound 2-aminobenzoic acid (4) was generated via reduction of the
nitro group located at C-2 into a primary amine (Fig. 14)
Figure 14: Reaction mechanism showing reduction of 2-nitrobenzoic acid into 2-aminobenzoic acid in presence of
Pd/C and hydrazine
The 2-nitrobenzoic acid starting material (1, Fig. 14) was reduced in the presence of a
carbon-activated palladium catalyst and hydrazine hydrate to convert the nitro group into a
primary amine thus affording the 2-aminobenzoic acid product (4, Fig. 14) The carbon-activated
palladium catalyzes the generation of hydride ions followed by a series of proton transfer
reactions, which go on to reduce the nitro group into an amine, which also generates water and
nitrogen gas side products.
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Reaction b (Fig. 14) was run in ethanol (EtOH) and refluxed for a period of 1.5 hours
with constant stirring under inert environment conditions (argon atmosphere) (Fig. 15). The
completed reaction mixture was filtered via cotton plug to remove Pd/C (Fig. 16) and the EtOH
solvent was evaporated under reduced pressure. Product yields ranged from 60 - 80%.
Figure 15: General setup for a refluxed reaction. Reaction vessel is heated via hot plate and evaporating solvent is
condensed back into the reaction vessel via glass condenser cooled with running water
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Figure 16: Overview of cotton plug filtration
3.2.1.3 Intermediate Product Synthesis – Reaction c
Intermediate compounds 9-chloro-1,2,3,4-tetrahydroacridine (9Cl-THA) and its C-6 and
C-7 chloro-derivatives (7, 8, 9) were synthesized via multistep reaction mechanism where
nucleophilic substitution, and elimination reactions occur (Fig. 17).
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Figure 17: Reaction mechanism outlining the generation of 9-chloro-1,2,3,4-tetrahydroacridine derivatives in the
presence of POCl3
The mechanism of Reaction c begins by the nucleophilic attack of the carbonyl carbon of
cyclohexanone by the primary amine of 2-aminobenzoic acid (4, 5, or 6, Fig. 17). The carbonyl
oxygen of cyclohexanone also acts as a nucleophile attacking the carboxylate thus creating a 6-
membered ring and eventually the desired tricyclic molecule. The reaction occurs in the presence
of POCl3 which generates chlorine to displace oxygen in order to afford the final 9-chloro-
1,2,3,4-tetrahydroacridine product and its C-6 and C-7 chloro derivatives (7, 8, or 9, Fig. 17)
Reaction c was carried out in the presence of cyclohexanone and POCl3 and kept under
reflux for 2.5 hours (Fig. 15). The reaction mixture was poured on ice after cooling and mixed
with excess ice water. Any formed precipitate was filtered off and the aqueous fraction was
neutralized with sodium bicarbonate where further precipitate formed. The precipitate was again
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filtered, combined, and dissolved in dichloromethane (DCM). The DCM fraction was washed
with brine, then dried with magnesium sulphate (MgSO4) and evaporated under reduced pressure
(Fig. 13). The product was run through flash chromatography for further purification using DCM
(Fig. 18). Product yields ranged from 50 – 80 %.
Figure 18: Overview of flash chromatography set up
3.2.1.4 Final Product Synthesis – Reaction d
Final test compounds were synthesized via a nucleophilic aromatic substitution at the C-9
position using an amine nucleophile as shown in Figure 19.
Figure 19: Reaction mechanism of amine coupling to THA catalyzed by NaI
25
The 9Cl-THA derivatives (7, 8, or 9, Fig. 19) were converted into the 6 or 7-chloro and
unchlorinated benzylamine, substituted benzylamine, and picolylamine-substituted compounds
(10a-d, 11a-e, 12a-e, 13a-f, Fig. 19). The starting material (7, 8, or 9) was dissolved in a solvent
which allows NaI to dissociate. The iodine ion displaces the chlorine located at C-9, thus
creating a better leaving group for further nucleophilic attack (Fig. 19). The amine nucleophiles
(substituted/unsubstituted benzylamine, or picolylamine) displace iodine at C-9 to afford the
final test compound.
Reaction d (Fig. 19) was carried out in the presence of either phenol or butanol with NaI
as a catalyst and run under reflux for 3 – 4.5 hours (Fig. 15). The resulting solution was dried
under reduced pressure and re-dissolved in DCM then washed 3 times with concentrated brine
solution (Fig. 13). The organic fraction was dried with MgSO4 and evaporated under reduced
pressure. The resulting product was purified via flash chromatography (solvent: DCM) with
multiple rounds if necessary (Fig. 18). Product yields ranged from 12 – 47%.
3.3 Biological Evaluation
The biological profiles of synthesized compounds were evaluated, focusing on initial
evaluation of i) ChE inhibition, followed by ii) antioxidant capacity, iii) chelation capacity, and
finally evaluation of iv) cell viability in order to demonstrate the full SAR of top derivatives
(Fig. 20).
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Figure 20: General outline of biological evaluation
3.3.1 Cholinesterase inhibition Assay
Inhibitory concentration (IC50) values toward hAChE and hBuChE were determined for
each test compound following the Ellman’s method.65 This colorimetric assay works by
incubating test compounds with a solution containing either hAChE or hBuChE in the presence
of a thiocholine analogue (acetylthiocholine or butyrylthiocholine). The ChEs hydrolyze their
respective substrates to generate thiocholine, which will go on to react with 5,5'-dithiobis-(2-
nitrobenzoic acid) (DTNB). This generates a yellow chromophore that is detected via UV-
spectroscopy at 405-412 nm. Potent test compounds prevent ChE from hydrolyzing their
respective substrates, thus preventing the generation of yellow chromophore. The general assay
mechanism is illustrated in Figure 21.
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Figure 21: Mechanism of hAChE/hBuChE hydrolysis of acetylthiocholine/butyrylthiocholine and thiocholine
interaction with DTNB to generate a yellow chromophore
28
3.4 Antioxidant Assay
The assessment of test compound capacity to scavenge ROS was accomplished via the
2,2-diphenyl-1-picrylhydrazyl (DPPH) assay protocol.66 DPPH exists as a stable free radical in
crystalline form where it takes on a purple colour (Fig. 22). It has an absorbance peak at a
wavelength of 517 nm, which decreases when the free radical is quenched by an antioxidant. The
colour change is directly proportional to the ability of molecules to act as potential antioxidants.
The results were compared with reference agents curcumin and trolox.
DPPH● DPPH-R’
Figure 22: Absorbance shift of DPPH upon quenching of free radical
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3.5 Chelation Assay
The metal-chelation assay protocol outlined by Karamac and coworkers, is a UV-vis
spectroscopy-based experiment, which quantifies the chelation ability percentage of a given test
compound.67 It is a competitive assay where test compounds compete with ferrozine, a known
chelator. The ability of test compounds to chelate iron can be monitored by a decrease in
absorbance at 562 nm.
As a competitor chelator is introduced, it will begin to chelate the Fe2+ or Fe3+ ions
resulting in a decrease in the absorbance at 562 nm (Fig. 22).
Figure 23: Shift in ferrozine absorbance upon iron chelation. Inhibition of ferrozine chelation and absorbance shift
due to test compound chelation of iron
3.6 Evaluation of Cell Viability
The screening of cell viability follows a previously outlined methodology by Mosman,
known as the MTT assay protocol.68 SH-SY5Y neuroblastoma cells, like other living cells,
reduce the reagent 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT reagent)
from a yellow chromophore into a purple formazan (absorption at 570 nm) via activity of the
mitochondrial dehydrogenase (MDH) (Fig. 24). As cells die, MDH activity of the enzyme is
reduced and the reduction of MTT reagent does not occur and is directly correlated to the percent
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of living cells in a culture.  This can be correlated to the toxicity profile of a test compound by
observing the relationship between test compound and its capacity to maintain cell viability.
Figure 24: Mechanism of MTT assay with viable cell reduction of MTT to formazan
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CHAPTER IV
Results and Discussion
4.1 Structure-Activity Relationship (SAR) Studies
Obtaining the relationship between different compound structures and their biological
effects is an integral part of medicinal chemistry research. Structural modifications were utilized
to assess the impact on the overall biological profile of target derivatives. This was ultimately
done to answer the question of whether a series of THA derivatives could potentially target the
cholinergic and oxidative stress pathways of AD.
4.2 Anti-cholinesterase Evaluation
The biological anti-ChE profiles of each compound were assessed. Two major classes of
compounds make up the entirety of the chemical library developed based on C-9 groups: i)
benzylamine and substituted benzylamine series; ii) picolylamine series.
4.2.1 Benzylamine and Substituted Benzylamine Series
The anti-ChE activity of test compounds carrying benzylamine and substituted
benzylamine, are expressed as IC50 values; the concentration of test compound required to inhibit
50% of ChE enzyme activity. Selectivity indices (SI) indicate the selectivity of test compounds
toward ChE enzymes with higher numbers indicating AChE selectivity. Other molecular
parameters such as partition coefficient (ClogP), and molecular volume (MV – Å3) are also given
in Table 1.
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Table 1: ChE IC50 values, SI, ClogP, and MV for benzylamine and substituted benzylamine compounds (10a-d,
11a-e, and 12a-e)
Cpd C-6 C-7 R2 R3 R4 ChE IC50 (µM)a SIb ClogPc MVd(Å3)AChE BuChE
10a H H H H H 6.96 0.41 0.059 5.52 203.39
10b H H OMe H H 5.81 0.089 0.015 5.44 223.98
10c H H H OMe H 3.34 0.079 0.024 5.44 223.98
10d H H H OMe OMe 2.23 0.024 0.011 5.18 249.36
11a Cl H H H H 1.67 3.99 2.4 6.33 219.05
11b Cl H OMe H H 2.98 2.38 0.8 6.25 237.76
11c Cl H H OMe H 0.61 5.22 8.6 6.25 237.76
11d Cl H H H OMe 0.72 9.10 12.6 6.25 237.76
11e Cl H H OMe OMe 0.85 1.40 1.6 5.99 260.33
12a H Cl H H H 2.59 12.11 4.7 6.33 219.05
12b H Cl OMe H H 5.1 4.25 0.83 6.25 237.76
12c H Cl H OMe H 1.89 8.25 4.4 6.25 237.76
12d H Cl H H OMe 3.37 11.65 3.5 6.25 237.76
12e H Cl H OMe OMe 1.26 9.27 7.4 5.99 260.33
Tacrine – Cognex® 0.215 0.050 0.41 3.27 139.90
Donepezil – Aricept® 0.03 3.60 0.009 4.60 271.00
Galantamine – Reminyl® 3.20 12.60 0.3 1.00 179.20
aIC50 values are the average of two to three separate experiments (duplicates/n = 2) with mean deviation of < 10% ofaverage. bSI = hBuChE IC50/hAChE IC50. cClogP was determined using ChemDraw UIltra v11.0 CambridgeSoftware Company. dMV was calculated using the Discovery Studio from Accelrys Inc.
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The SAR data for this class of compounds indicates that they exhibit cholinesterase
inhibition from nM to µM range (hAChE IC50 61 nM - 6.96 µM; hBuChE IC50 0.61; 24 nM -
11.65 µM). In the substituted 1,2,3,4-tetrahydroacridin-9-amine series of compounds 10a-d, the
presence of a benzyl substituent at C-9 position in 10a provided dual inhibition of both AChE
and BuChE. This compound was a selective BuChE inhibitor (BuChE IC50 = 0.41 µM). The
addition of an OMe substituent ortho (R2 = OMe, R3 = R4 = H) to C-9 benzyl group in 10b led to
a 4.6-fold increase in its potency toward BuChE (IC50 = 89 nM) and a moderate gain in AChE
inhibition (IC50 = 5.81 µM) relative to 10a. Furthermore, regioisomeric replacement of ortho-
OMe substituent with a meta-OMe (R2 = H, R3 = OMe, R4 = H) as in 10c provided further
enhancement in BuChE inhibitory potency (IC50 BuChE = 79 nM) and further gain in AChE
inhibitory potency (IC50 = 3.34 µM). Interestingly, the presence of a 3,4-diOMe substituent as in
compound 10d (R2 = H, R3 = R4 = OMe), provided the best combination of dual cholinesterase
inhibition among this series. Compound 10d was the most potent BuChE inhibitor in this series
(IC50 = 24 nM) and was much more potent relative to reference agents tacrine, donepezil and
galantamine (Table 1). Furthermore, this compound was the most potent AChE inhibitor in this
series (AChE IC50 = 2.23 µM). The AChE inhibitory potency order was 3,4-diOMe (10d) > 3-
OMe (10c) > 2-OMe (10b) > H (10a). It is interesting to note that all compounds in this series
exhibited selective inhibition of BuChE enzyme.
In the 6-chloro-substituted-1,2,3,4-tetrahydroacridin-9-amine series of compounds 11a-e,
the presence of a C-6 chlorine atom had a dramatic effect on BuChE inhibition and resulted in
weaker inhibition relative to substituted 1,2,3,4-tetrahydroacridin-9-amine series of compounds
10a-d. In contrast, the presence of the C-6 chlorine led to superior AChE inhibition (AChE IC50
= 0.61-2.98 µM). Compounds 11c-d (AChE IC50 = 0.61 - 0.85 µM range) exhibited better AChE
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inhibitory potency relative to galantamine although they were not as potent as tacrine (Table 1).
It appears that for this class of compounds, the BuChE inhibition was sensitive to both the
presence of C-6 chlorine and the position of OMe substituents. For example the presence a para-
OMe substituent (R2 = H, R3 = H, R4 = OMe) as in compound 11d, led to weak inhibition of
BuChE (IC50 = 9.1 µM). The compound with a good combination of dual AChE and BuChE
inhibition in this series was 11e with a 3,4-diOMe-substituent (AChE IC50 = 0.85 µM; BuChE
IC50 = 1.4 µM) whereas compound 11c was the most potent AChE inhibitor (IC50 = 0.61 µM). It
is interesting to note that all the compounds in this series except compound 11b, exhibited
selective inhibition of AChE.
In the 7-chloro-substituted-1,2,3,4-tetrahydroacridin-9-amine series of compounds 12a-e,
the presence of a C-7 chlorine decreased both AChE and BuChE inhibition and potency relative
to C-6 series (AChE IC50 = 1.26 - 5.10 µM range and BuChE IC50 = 4.25 - 11.65 µM range,
Table 1). Compound 12e (3,4-diOMe, R2 = H, R3 = R4 = OMe) was the most potent AChE
inhibitor in this series (AChE IC50 = 1.26 µM) whereas compound 12b with an ortho-OMe (R2 =
OMe, R3 = R4 = H) substituent was the most potent BuChE inhibitor (BuChE IC50 = 4.25 µM).
Similar to the 6,9-chloro-substituted-1,2,3,4-tetrahydroacridin-9-amine series of compounds,
they all exhibited better AChE selectivity except for compound 12b.
The ClogP values, a measure of partition coefficient, for this series of compounds
calculated computationally were in the range of 5.18 to 6.33 (donepezil ClogP = 4.60) which
indicates their ability to cross the blood brain barrier. However, it should be noted that ClogP
values for the 6 and 7-chloro-substituted-1,2,3,4-tetrahydroacridin-9-amine series of compounds
11a-e and 12a-e are relatively high which suggests potential toxicity concerns. In contrast, the
lack of chlorine in the substituted-1,2,3,4-tetrahydroacridin-9-amine series of compounds 10a-d
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provided acceptable ClogP values (ClogP = 5.18-5.52, Table 1). Furthermore, the molecular
volume of these compounds was in a range of 203.39 to 260.33 Å3 which indicates their ability
to bind to both AChE and BuChE enzymes and exhibit dual inhibition.
In summary, these studies indicate that the presence of chlorine at either C-6 or C-7
position of the tetrahydroacridine ring had a significant impact on AChE inhibition and potency.
Figures 25 and 26 compare the relative potencies of these compounds toward AChE and BuChE.
The presence of a C-6 chlorine provided superior AChE inhibition (11a-e) whereas
regioisomeric placement of chlorine at C-7 led to a decrease in AChE and BuChE inhibitory
potency (12a-e). In contrast, non-chlorinated 1,2,3,4-tetrahydroacridin-9-amine derivatives (10a-
d) exhibited selective and nM potency toward BuChE inhibition.
Figure 25: Summary of AChE IC50 values of benzylamine and substituted benzylamine series of compounds
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Figure 26: Summary of BuChE IC50 values of benzylamine and substituted benzylamine series compounds
Figure 27: Top ChEI from the benzylamine and substituted benzylamine series
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4.2.2 Picolylamine Series
The anti-ChE activity of test compounds carrying picolylamine groups are expressed as
IC50 values. Selectivity indices (SI) indicate the selectivity of test compounds toward ChE
enzymes with higher numbers indicating AChE selectivity. Other molecular parameters such as
partition coefficient (ClogP), and molecular volume (MV – Å3) are also given in Table 2.
Table 2: ChE IC50 values, SI, ClogP, and MV for picolylamine derivatives; compounds (13a-f)
Cpd C-6 C-7 ChE IC50 (µM)a SIb ClogPc MV (Å3)d
AChE BuChE
13a H H 6.65 0.073 0.011 4.02 201.00
13b H H 3.99 0.223 0.056 4.02 201.00
13c Cl H 0.095 1.61 16.9 4.83 215.74
13d Cl H 0.19 12.73 67.0 4.83 215.74
13e H Cl 7.06 6.78 0.96 4.83 215.74
13f H Cl 7.69 >25 - 4.83 215.74
Tacrine – Cognex® 0.215 0.050 0.41 3.27 139.90
Donepezil – Aricept® 0.03 3.60 0.009 4.60 271.00
Galantamine – Reminyl® 3.20 12.60 0.3 1.00 179.20
aIC50 values are the average of two to three separate experiments (duplicates/n = 2) with mean deviation of < 10% ofaverage value. bSI = hBuChE IC50/hAChE IC50. cClogP was determined using ChemDraw UIltra v11.0 CambridgeSoftware Company. dMV was calculated using the Discovery Studio from Accelrys Inc.
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In order to explore the effect of aromatic heterocycles at the C-9 position of the THA
template, derivatives (13a-f, Table 2) that contain either a 2- or 3-pyridyl ring were evaluated for
their ability to inhibit ChE enzymes. Interestingly, compound 13a which is the 2-pyridyl isomer
of compound 10a, was about 5.6-fold more potent toward BuChE enzyme (BuChE IC50 = 73
nM) compared to compound 10a.  However, this modification did not affect its AChE inhibition
(AChE IC50 = 6.96 µM). The presence of a 3-pyridyl substituent in 13b, provided superior
BuChE inhibition (IC50BuChE = 0.223 µM) relative to 10a, although it was not as potent as 13a.
In contrast, 13b exhibited superior AChE inhibition (AChE IC50 = 3.99 µM) compared to both
10a and 13a (Table 1 and 2). Both 13a and 13b exhibited selective BuChE inhibition which was
similar to the trend seen with compounds 10a-d (Table 1). Interestingly, the combination of a C-
6 chlorine and a 2-pyridyl substituent in 13c provided the most potent AChE inhibitor in the
entire compound library with nanomolar inhibition (AChE IC50 = 95 nM, Table 2). 13c is more
than twice as potent in AChE inhibition (AChE IC50 = 95 nM) relative to reference agent tacrine
(AChE IC50 = 215 nM, Table 2). However, the addition of C-6 chlorine in compound 13c was
detrimental to BuChE inhibition (BuChE IC50 = 1.61 µM) compared to 13a. Similarly,
compound 13d with a 3-pyridyl substituent was the second most potent AChE inhibitor (AChE
IC50 = 0.19 µM) identified in our compound library after 13c. However, 13d exhibited weak
BuChE inhibition (BuChE IC50 = 12.73 µM). In contrast, the C-7-chlorinated pyridyl isomers,
13e and 13f, turned out to be poor ChE inhibitors (AChE IC50 range: 7.06 - 7.69 µM; BuChE
IC50 range: 6.78 µM to no inhibition at 25 µM test concentration). It should be noted that the C-9
pyridyl series of compounds were less lipophilic relative to compounds 10a-d, 11a-e and 12a-e
series of compounds and exhibited ClogP values in the range of 4.02-4.83 which was comparable
to the marketed anti-AD agent donepezil (ClogP = 4.60, Table 1).
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Figure 28: Summary of AChE IC50 values of picolylamine series of compounds
Figure 29: Summary of BuChE IC50 values of picolylamine series of compounds
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Figure 30: Top ChEI from the picolyl series of derivatives
Our SAR studies suggest that in general, BuChE inhibition was sensitive to electronic
and steric parameters at C-9 position of the tetrahydroacridine ring whereas a chlorine
substituent at either the C-6 or C-7 position modulated AChE inhibition.
4.3 Antioxidant Capacity Evaluation
The biological antioxidant profiles of test compounds were assessed. Two major classes
of compounds make up the entirety of the chemical library developed: i) benzylamine and
substituted benzylamine; ii) picolylamine series.
4.3.1 Benzylamine and Substituted Benzylamine Series
The antioxidant activity of test compounds carrying benzylamine, and substituted
benzylamine are expressed as a percent inhibition at 100 µM which gives the ability of test
compounds to scavenge DPPH free radical.
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Table 3: DPPH percent inhibition (%) values for benzylamine and substituted benzylamine; compounds (10a-d,
11a-e, 12a-e)
Cpd C-6 C-7 R2 R3 R4 Percent Inhibition(%) at 100 µMa
10a H H H H H 12.3
10b H H OMe H H 10.4
10c H H H OMe H 8.5
10d H H H OMe OMe 9.3
11a Cl H H H H 10.8
11b Cl H OMe H H 10.8
11c Cl H H OMe H 7.9
11d Cl H H H OMe 9.5
11e Cl H H OMe OMe 7.2
12a H Cl H H H 9.0
12b H Cl OMe H H 6.3
12c H Cl H OMe H 10.4
12d H Cl H H OMe 8.1
12e H Cl H OMe OMe 10.9
Trolox 91.5
Curcumin 68.8
aPercent inhibition values are the average of two separate experiments (duplicate/n = 2) with mean deviation < 10%
of average value.
The benzyl and substituted benzylamine series of compounds demonstrated percent
inhibitions of the DPPH radical between 6 - 11 %.
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Comparing the compounds in Table 3 to the chemical structures of curcumin (Fig. 5) it
can be seen that the presence of a phenolic group is responsible for their antioxidant properties
(curcumin: 68.8 % inhibition, trolox: 91.5% inhibition). The test compounds do not possess
phenolic groups. Although they have methoxy groups, they are not considered as effective
antioxidants as was seen with their weak DPPH scavenging (% inhibition: 6.3 – 12.3%).
4.3.2 Picolylamine Series
The antioxidant activity of test compounds carrying picolylamine groups are expressed as
percent inhibition at 100 µM.
Table 4: DPPH percent inhibition (%) values for picolylamine derivatives 13a-f
Cpd C-6 C-7 Percent Inhibition (%) at
100 µMa
13a H H 11.0
13b H H 7.8
13c Cl H 7.2
13d Cl H 5.9
13e H Cl 11.5
13f H Cl 7.9
Trolox 91.5
Curcumin 68.8
aPercent inhibition values are the average of two separate experiments (duplicate/n = 2) with mean deviation < 10%
of average value.
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Like the substituted benzylamine series, the picolyl series of THA derivatives exhibit
percent inhibitions between 5.9 – 11.5% (Table 4) and thus demonstrate negligible antioxidant
effects.
When comparing the picolyl series for their antioxidant capacities to that of the reference
compounds (curcumin: 68.8% inhibition, trolox: 91.5% inhibition), it can be seen that the
phenolic group is a driving force in antioxidant capacity. Therefore, the picolyl series of
compounds are not effective antioxidants due to their by their weak DPPH scavenging capacity
(% inhibition: 5.9 – 11.5%), suggesting 2- or 3- pyridyl groups do not possess antioxidant
properties.
4.4 Metal Chelation
The iron chelation capacity of picolyl-type derivatives was determined via UV analysis in
the Fe(II)-ferrozine competition assay. The chelation capacity of test compounds is expressed as
percent chelation.
Table 5: Percent iron chelation (%) values for picolylamine derivatives 13a-f
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Cpd C-6 C-7 Percent Chelation (%) at
50 µMa
13a H H 9.4
13b H H 11.0
13c Cl H 14.5
13d Cl H 10.2
13e H Cl 20.2
13f H Cl 10.4
Clioquinol 63.5
Desferoxamine 67.1
aPercent chelation values are the average of two separate experiments (duplicate/n = 2) with mean deviation < 10%
of average value.
From Table 5, the relative percent chelation of test compounds range from 9.4 -20.2%
while references clioquinol and desferoxamine have percent chelation of 63 and 67%,
respectively. The C-9, 2-pyridyl series of compounds, 13a, 13c, and 13e, can form a chelating
center. Despite this, these compounds exhibited weak to moderate iron chelation. The maximum
chelation was seen for compound 13e (20.2%, Table 5). This can be explained by the presence of
an sp3 hybridized methylene (-CH2) group at C-9 that leads to bond rotation and hinders the
formation of a rigid chelation center. The weak iron chelation capacity exhibited by the 3-pyridyl
series of compounds 13b, 13d, and 13f, is not surprising since they do not form a chelation
center as the pyridyl nitrogen is at a greater distance from the C-9 secondary amine, relative to
the 2-pyridyl series of compounds.
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4.5 Evaluation of Cell Viability
The toxicity profiles of test compounds 10b-d, 11c,e, and 13a-d were evaluated using the
MTT assay protocol in order to assess their potential toxicity. Compounds were tested at 25 µM,
50 µM concentrations along with reference compound tacrine.
Table 6: Percent viability of SH-SY5Y neuroblastoma cell line after treatment with test compounds
Cpd Percent Viability
at 25 µM (%)a,b
Percent Viability
at 50 µM (%)a,b
ClogPc
10b 54.1 20.3 5.44
10c 95.5 26.8 5.44
10d 93.8 84.2 5.18
11c 2.8 1.7 6.25
11e 81.8 40.5 5.99
13a 58.9 47.2 4.02
13b 100.0 82.1 4.02
13c 75.4 18.1 4.83
13d 80.6 96.6 4.83
Tacrine 89.6 81.1 3.27
aData is expressed as mean ± SD, (n = 3) ANOVA analysis with Dunnett’s post-test. bDerivative’s cell viability data
obtained from the collaboration with Dr. Beazely’s group. cClogP was determined using ChemDraw UIltra v11.0
Cambridge Software Company
From Table 6, the range of cell viability for selected test compounds ranged from as low
as 1.7% to as high as 100% viability. Compounds chosen from Table 1 and Table 2 were those
that demonstrated potent ChEI activity.
It was observed that for compounds 10b, 10c, and 10d, the presence of a dimethoxy-
substituted benzyl group (10d) significantly improved the cell viability at a concentration as high
as 50 µM (84.2%) compared to mono-OMe compounds, 10b and 10c (cell viability = 20.3 –
26.8%, respectively). This can be attributed to the difference in ClogP values between the mono
versus diOMe compounds. The increased ClogP of 10b and 10c led to increased cell toxicity as
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compared to the diOMe compound, 10d (cell viability = 93.8 and 84.2% at 25 µM and 50 µM,
respectively). However, it may not be the ClogP values alone which dictate cell viability. We
also see that the mono-OMe derivative 11c with one of the highest ClogP values in the chemical
library (6.25) promotes significant cell death in the neuroblastoma cell line at both 25 µM and 50
µM.   Finally, the picolylamine series of compounds (Table 2) had lower ClogP values (Table 6)
as compared to the substituted benzylamine series. Compounds 13b and 13d exhibited good cell
viability at both 25 µM and 50 µM concentrations (100%, 82.1%, and 80.6%, 96.6%,
respectively). However, compounds 13a and 13c were toxic to cells at 50 µM (Table 6). These
studies indicate that the cell viability was sensitive to both the ClogP values as well as the nature
of substituents at C-6, C-7, and C-9 positions.
Figure 31: Summary of cell viability percentages of THA test compounds after 24 h incubation with SH-SY5Y
neuroblastoma cells. Control (not shown) represents 100% viability. Error bars represent average of standard error.
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4.6 Molecular Modeling
Computational modeling studies were utilized to help corroborate and better understand
the findings determined in the biological ChE evaluation of test compounds. This section aims to
describe the binding modes of a few potent ChEI and their comparisons within hAChE and
hBuChE active sites. Only key residues are highlighted with hydrogen atoms removed for
clarity.
Figure 32: Docking of N-(3-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (10c, light blue ball and stick) and
N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (10d, dark blue, ball and stick) in the active site of
hAChE (left) and hBuChE (right). Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen atoms are
not shown for clarity. Red: Catalytic triad; Orange: Cationic site; Yellow: Acyl pocket; Green: Stabilizing residues;
Blue: PAS (AChE) and PAS analogue (BuChE)
The binding mode of 10c in hAChE (PDB: 1B41) (Fig. 32) demonstrates an almost
planar orientation whereby the THA moiety of the compound is located in the PAS with its
nitrogen group forming strong hydrophobic interactions with Trp286 (distance ≈ 3.4 Å). The
aliphatic ring of THA also spans into the acyl pocket where it interacts with Phe295 (distance ≈
3.2 Å), and interacts with Tyr341 (distance ≈ 4.9 Å). Moving further toward the active site, the
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C-9 amine forms strong van der Waals interactions with residues Tyr341 and Tyr337 (distance ≈
4.3 Å and 4.0 Å, respectively). Finally, the C-9 group extends into the active site where it
interacts with the catalytic Ser203 and His447 (distance ≈ 4.7 Å and 5.1 Å, respectively). The
methoxy group also anchors the molecule within the active site by forming hydrogen bonds with
Tyr337 (distance ≈ 3.5Å), and leans against Trp86 (distance ≈ 3.8 Å). Overall this compound
spans the length of the PAS and acyl pocket, even interacting with catalytic and cationic site
residues, which explains its AChE inhibition (IC50= 3.34 µM; 10cMV = 223.98 Å3).
The addition of a diOMe-benzyl substituent to the C-9 group in 10d proved to have a
significant effect in the compound binding mode within the AChE active site. 10d is oriented
such that its THA moiety leans entirely against the acyl pocket where the THA nitrogen forms
direct hydrogen bonding interactions with Phe295 (distance ≈ 3.3 Å). The C-9 amine forms van
der Waals contacts with Trp286 and Tyr341 (distance ≈ 4.5 Å and ~ 4.3 Å, respectively). The C-
9 group is rotated about its axis such that it is perpendicular to the THA base. The molecule is
mostly PAS localized with the C-9 group protruding out of the enzyme. Overall the compound
creates a stable plug through hydrophobic and hydrogen bonding interactions in the acyl pocket
and PAS thus preventing substrates from entering AChE. These observations indicate its superior
AChE inhibition (IC50 = 2.23 µM) relative to 10c.
When comparing 10c and 10d we find that although their spatial orientation in the
enzyme differs, they are both mostly PAS localized and are stabilized by several polar and non-
polar interactions with residues in this region, thus they act to block entry of substrates into the
enzyme active site.
The binding mode of 10c differs significantly when observed in hBuChE (PDB: 1PO1).
The molecule sits between the cationic and catalytic site with the THA nitrogen forming a direct
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hydrogen bond with Trp82 (distance ≈ 3.4 Å). The fused benzyl ring of THA also forms
hydrophobic interactions with His438 (distance ≈ 3.6 Å). The molecule sits at an angle to Trp82
with the C-9 group of the molecule directed into the acyl pocket. The C-9 amine also interacts
with aromatic residue Phe329 (distance ≈ 3.4 Å). The C-9 group is oriented perpendicularly to
the THA base with the 3-methoxy group directed away from the catalytic site. The C-9 benzene
ring interacts with both catalytic Ser198 and His438 (distance ≈ 4.4 Å) with the 3-methoxy group
sitting between acyl pocket residues Leu286 (distance ≈ 3.8 Å from the backbone) and Val288
(distance ≈ 3.7 Å). Its superior and selective inhibition for BuChE (IC 50 = 0.079 µM) can be
attributed to the observations above that it forms strong hydrophobic and hydrogen bonding
interactions with key residues in the active site. By blocking Trp82, as well as the catalytic and
acyl pocket residues, it effectively prevents ACh hydrolysis.
The binding mode of 10d in hBuChE differs by the slight angle in which it sits in the
active site (Fig. 32). Unlike 10c, 10d lays parallel with Trp82 with the C-9 group pointing away
from the catalytic triad. The THA nitrogen and carbons form hydrophobic interactions with
Trp82 ranging from 3.9 – 4.3 Å away, thus completely covering the residue. The THA base also
forms hydrophobic interactions between the fused benzene ring of Ser198 (distance ≈ 4.9 Å) and
the aliphatic ring of His438 (distance ≈ 4.5 Å). The C-9 group is rotated such that its benzene
ring is perpendicular to THA with the 3-OMe substituent interacting with the backbone of Trp82
(distance ≈ 3.6 Å). This explains the potent BuChE inhibition seen with 10d (IC50 = 0.024 µM).
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Figure 33: Docking of 6-chloro-N-(3-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (11c, salmon, ball and
stick) and 7-chloro-N-(3-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (12c, purple, ball and stick) in the
active site of hAChE. Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen atoms are not shown
for clarity. Red: Catalytic triad; Orange: Cationic site; Yellow: Acyl pocket; Green: Stabilizing residues; Blue: PAS
(AChE)
The binding mode of 11c in hAChE (PDB: 1B41) (Fig. 33) indicated that the molecule
was able to span all the way from the active site gorge to the PAS. It can also be seen that the
THA template is situated in the active site while the C-9 methoxy-benzylamine group is directed
toward the PAS. The THA template is situated atop Trp86; however it did not lay parallel to the
residue, instead taking on an approximate 50º angle. Additionally, the THA template and C-6
chloro substituent form strong van der Waals contact with the Trp86 backbone (distance ≈ 3.8
Å). This C-6 chloro group is pointed opposite to the catalytic triad residues with the aliphatic
ring of the THA base forming strong hydrophobic interactions with the catalytic Ser203,
(distance ≈ 3.6 Å), and His447 (distance ≈  3.4 Å).  Moving toward the C -9 secondary amine, we
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see the amine forming hydrogen bonds with the aromatic residue, Tyr337 (distance ≈ 2.7 Å). The
C-9 group is oriented such that the benzyl ring is rotated perpendicularly to that of the THA base.
This benzyl ring forms hydrophobic interactions with Phe297, a key residue in the acyl pocket
(distance ≈ 3.7 Å). In addition, the 3-OMe substituent forms hydrophobic interactions with a key
residue of the PAS, Trp286 (distance ≈ 3.2 Å). Overall, the molecule is in a non-planar
conformation, and is situated such that its THA base is located above Trp86 and spans the length
of the active site to the PAS. These observations account for its potent AChE inhibition (IC50 =
0.61 µM)
Alternatively the spatial orientation of the 7-chloro isomer, 12c, significantly differs from
11c. The THA base of 12c points toward the entrance of AChE with the C-9 group pointing
toward the active site. The molecule is also non-planar with the C-9 group slightly bent laterally
toward the C-7 chloro-substituted aromatic ring of THA. The molecule is almost entirely PAS
localized forming strong hydrophobic interactions between the C-9 amine and Tyr341 (distance
≈ 3.6 Å). The C-9 3-methoxy-benzyl group forms strong hydrophobic interactions with the acyl
pocket being ~ 3.3 Å away from Phe297. The C-9 group points toward the active site; however,
it is ~10 Å away from the catalytic triad.
The observation that 12c is able to block the entrance into AChE, while forming
hydrophobic interactions with several key residues demonstrates why it has a low µM IC50
toward AChE (1.89 µM) (Fig. 33). However, it is apparent that the hydrogen bonding,
hydrophobic interactions, and blocking of key residues in the active and catalytic site make 11c a
more potent AChE inhibitor (IC50 = 0.61 µM), and thus a simple isomeric change from C-6 to C-
7 chlorination can have a significant impact in receptor-ligand binding interactions, which affects
AChE inhibition.
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Figure 34: Docking of N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (10d, light blue, ball and stick)
and 6-chloro-N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (11e, green, ball and stick) in the active
site of hAChE (left) and hBuChE (right). Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen
atoms are not shown for clarity. Red: Catalytic triad; Orange: Cationic site; Yellow: Acyl pocket; Green: Stabilizing
residues; Blue: PAS (AChE) and PAS analogue (BuChE)
The binding mode of 10d and 11e in hAChE (PDB: 1B41) (Fig. 34) was investigated to
determine the differences in the receptor-ligand interactions which illustrate 11e’s superior
potency (IC50 = 0.85 µM) over 10d (IC50 = 2.23 µM) toward AChE. From Figure 34, it can be
seen that 10d is entirely PAS localized with the THA base pointing toward the acyl pocket ~ 3.4
Å away from Phe295, forming hydrogen bonds with the backbone of Phe295 and THA nitrogen.
The C-9 group is rotated such that it is perpendicular to the THA base and it protrudes from the
enzyme. The C-9 amine also forms van der Waals contact with the Trp286 in the PAS (distance
≈ 4.5 Å), and the stabilizing region with Tyr341 (distance ≈ 4.3 Å) as it is situated between these
two residues. The C-9 group’s 3-methoxy substituent is also directed toward stabilizing residue
Tyr341 (distance ≈ 5.2 Å).
Alternatively, the receptor-ligand interactions between AChE and 11e show that the
compound is situated primarily in the active site gorge. The THA base sits deep into the gorge as
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it forms hydrogen bonds between its nitrogen and the backbone of the cationic site residue,
Trp86 (distance ≈ 3.5 Å). The molecule is not planar and takes on a “C”-shape. The C-6 chloro
group is pointed away from the catalytic site with the aliphatic ring of THA pointed directly
toward the catalytic triad. This ring forms polar interactions with Ser203 and His447, (distance ≈
4.5 Å and 4.0 Å, respectively). The C-9 amine is anchored into the active site by forming
hydrogen bonds with Tyr337 (distance ≈ 1.9 Å). Moving toward the C-9 group, we see that it
folds slightly inward and lays against Tyr341 ~3.7 Å away. The OMe substituents are directed
opposite to the acyl pocket and are located between Tyr341 and Trp286. Strong hydrophobic
interactions are formed between the OMe and Trp286 (distance ≈ 4.2 Å).
Furthermore, 11e spans the length of the active site all the way to the PAS, unlike 10d. It
is anchored by hydrogen bonds and hydrophobic interactions with residues in the cationic site
and catalytic triad, thus affording superior AChE inhibition.
As discussed previously in relation to Figure 34, 10d acts to inhibit hBuChE (IC50 =
0.024 µM) by completely blocking off Trp82 in the active site from stabilizing incoming
substrates through hydrophobic interactions. Its tricyclic THA rings, the largest portion of the
molecule, sits deep in the active site. Alternatively, 11e (BuChE IC50 = 1.4 µM) has a
significantly different binding mode where its C-9 group is directed into the active site and its
THA base directed toward the enzyme entrance. The aliphatic ring is directed into the acyl
pocket ~3.4 Å from Leu286 and ~4.8 Å from Val288. The C-9 group extends toward the
catalytic site where van der Waals occur between His438 and the 3-OMe substituent interacting
with the backbone of His438 (distance ≈ 3.6 Å). Finally the 4 -OMe substituent forms a hydrogen
bond with Trp82 (distance ≈ 2.8 Å).
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Our studies indicate the need for the THA moiety to be within the active site in order to
afford superior BuChE inhibition. The presence of a chlorine group at the C-6 position forces the
molecule to flip along its horizontal axis with the C-9 group binding within the active site.
Although the hydrogen bonding and hydrophobic interactions corroborates 11e’s µM IC50 for
BuChE, the lack of a chlorine in 10d allows the molecule to sit deeper into the active site and
afford nM IC50 values.
Figure 35: Docking of N-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine (13a, light blue, ball and stick)
and 6-chloro-N-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine (13c, purple, ball and stick) in the active site
of hAChE (left) and hBuChE (right). Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen atoms
are not shown for clarity. Red: Catalytic triad; Orange: Cationic site; Yellow: Acyl pocket; Green: Stabilizing
residues; Blue: PAS (AChE) and PAS analogue (BuChE)
The binding mode of 13a (IC50 = 6.65 µM) and 13c (IC50 = 0.095 µM) in hAChE (PDB:
1B41) (Fig. 35) illustrates the differences that occur when a chlorine group is added to a non-
chloro picolylamine series derivative. 13a is in an almost planar conformation with its THA
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group pointed toward the catalytic triad; specifically perpendicular to a virtual bridge between
His447 and Ser203. The THA base forms hydrogen bonds with the catalytic Ser203 (distance ≈
3.5 Å), and strong van der Waals interactions with the imidazole nitrogen of His447 (distance ≈
4.4 Å). The fused benzene ring of the THA base is pointing toward the acyl pocket (distance ≈
5.8 Å) thus forming van der Waals interactions, whereas the cyclohexyl ring is leaning against
Trp86 ~4.6 Å away. The C-9 group is parallel to the cationic pocket ~5 Å away from Trp86 with
the picolyl nitrogen forming strong van der Waals interactions with the backbone of Trp86
(distance ≈ 4 Å). Overall the compound is situated in the active site maintaining a planar
conformation where it is able to block key residues in the acyl pocket and cationic site.
The presence of a chlorine group at the C-6 position in 13c does not conform to a planar
structure with its THA base in the active site situated atop of Trp86 (distance ≈ 3.5 Å). The THA
nitrogen forms strong van der Waals interactions with the Trp86 indole nitrogen (distance ≈ 3.8
Å), with the chlorine group of the THA base pointing toward the catalytic triad ~4.0 Å away
from the backbone of His447.  The same THA nitrogen also forms hydrogen bonds with key
stabilizing residue Trp337 ~2.8 Å away. Moving away from the THA base, the C-9 amine also
undergoes strong hydrophobic interactions with Trp86 (distance ≈ 4.0 Å). The C-9 picolyl group
is rotated such that the compound is in a “C”-shape conformation with the picolyl group pointing
toward the acyl pocket and its nitrogen pointing toward the PAS.
Ultimately, the hydrogen bonding and hydrophobic interactions of 13a attributes to its
weak µM IC50 (6.65 µM). However, 13c’s “C”-shape conformation and localization in the active
site allows it to maintain strong hydrogen bonding and hydrophobic interactions in the active
site, unlike 13a, attributing to its far superior binding to AChE (IC50 = 0.095 µM).
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CHAPTER V
Conclusion and Future Studies
5.1 Conclusion
Over the course of this research project, a compound library of 20 THA-based derivatives
were designed, synthesized via 3-4 step reactions, and biologically tested against AChE, BuChE,
ROS, and metal chelation.
Compound design was established through review of past literature discussing the most
optimal functional groups to create a multi-target compound followed by computational
modelling studies to further assess compound potential. Chemical library development utilized a
wide range of chemical syntheses with yields ranging between 12 – 82%. Biological evaluations
were accomplished with previously developed protocols optimized for the purpose of this
project. Computational modelling was re-examined after biological profiles were established on
SAR data to substantiate generated results with their enzyme binding patterns. A summary of
drug properties are outlined below:
Molecular Weights (MW): 288.38 - 382.88 Da
Molecular Volume (MV): 201.00 - 260.33 Å3
Partition Coefficient (ClogP): 4.02 – 6.33
AChE Inhibition (IC50): 0.095– 7.69 µM
BuChE Inhibition (IC50): 0.024 – >25 µM
Antioxidant Capacity (% Inhibition): 5.9 – 12.3%
Chelation Capacity (% chelation): 9.4 – 20.2%
Neuroblastoma Cell Viability (at 25 µM and 50 µM): 1.7 – 100%
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When examining the ChE activity profiles of the 20 C-9 substituted THA derivatives, all
derivatives but one (19 total) demonstrated dual-ChE inhibition (Table 1 and 2). Many
compounds showed significant AChE inhibition with values as low as 0.095 – 0.85 µM (11c – e,
13c – d), which are more potent than the marketed agent galantamine (AChE IC50: 3.20 µM) and
comparable to tacrine (AChE IC50: 0.215 µM). These compounds fell into the group of C-6
chlorinated derivatives. The most potent compound being 13c (6-chloro-N-(pyridin-2-ylmethyl)-
1,2,3,4-tetrahydroacridin-9-amine; AChE IC50: 0.095 µM) with AChE inhibition greater than
that of tacrine and galantamine, but not as potent as donepezil (AChE IC50: 0.032 µM). The non-
chlorinated series proved to show exceptional BuChE inhibition (10b – d, 13a; BuChE IC50:
0.024 – 0.089 µM), with 10d (N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine;
BuChE IC50: 0.024 µM) being the most potent. It demonstrates superior BuChE inhibition
compared to that of donepezil (BuChE IC50: 3.2 µM), galantamine (BuChE IC50: 13.2 µM), and
tacrine (BuChE IC50: 0.06 µM).
In order to establish a multi-target candidate, all compounds were screened for their
antioxidant properties. With antioxidant capacity ranging between 5.9 – 12.3% DPPH
scavenging, as compared to curcumin (68.8%) and trolox (91.5%), the antioxidant profiles of test
compounds appear weak to negligible. Ultimately, it was concluded that lack of a hydroxy (OH)
group attached to the C-9 functionality is the primary reason for the weak antioxidant findings.
Introduction of a phenolic side chain would potentially afford significantly increased antioxidant
capacity.
Finally, select compounds (13a – f) were assessed for proof-of-concept to chelate metal
ions, specifically iron. The picolylamine-substitute series of compounds showed chelation
capacities ranging between 9.4 – 20.2%, with 13e (7-chloro-N-(pyridin-2-ylmethyl)-1,2,3,4-
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tetrahydroacridin-9-amine) being the most potent of the series (20.2%), showcasing a third of the
chelation capacity of reference compounds clioquinol (63.5%) and desferoxamine (67.1%).
Although it was able to chelate, it was relatively weak potentially due to a non-rigid chelating
center and varying bond angles between the picolylamine nitrogen and the C-9 amine.
SH-SY5Y neuroblastoma cell viability was assessed in the presence of test compounds
and had significant ranges between 1.7 – 100% viability. Differences in cell viability were the
result of varying combinations between lipophilicity, bioisosterism, and isomerism.
The acquired SAR for the tacrine based derivates strongly supports their use as ChEI for
both AChE and BuChE.
5.2 Future Studies
With our current SAR and biological profiles, future studies pertaining to this research
include further development of THA-based derivatives with C-9 catechol- and guaiacol
substituted benzylamines to improve the antioxidant profile and metal chelation properties. As
previously discussed, the possible loss of a chelation center accounts for the weak chelating
ability of the 2-picolyl class of compounds would lead us to explore pyrimidine groups.
Additionally a viable option in order to improve chelation capacity is to remove the methylene (-
CH2) at C-9 to prevent bond rotation. Another alternative is to convert the fused cyclohexyl ring
of THA into a piperazine (2 nitrogens on a non-aromatic ring) which would also create a
chelation center with favourable bond angles.
Finally, replacing the C-9 2-pyridinyl ring with a thiophene or furan ring will allow us to
explore metal chelation and antioxidant capacity with sulphur and oxygen as opposed to the
picolyl nitrogen and 5-membered versus 6-membered rings (Fig. 36).
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Expanding the SAR of lead compounds would include exploring other pathological
parameters of AD such as Aβ aggregation inhibition, inflammation, as well as neurofibrillary
tangle inhibition. The developed test compounds demonstrate in silico that they may be of
benefit in the inhibition of AChE-promoted Aβ aggregation whereby test compounds that contain
a 3,4-dimethoxybenzyl pharmacophore may be PAS localized (Fig. 32 and 33). As mentioned,
the PAS is a key region where Aβ peptides can anchor and form senile plaques promoting AD
pathology. It is of therapeutic benefit to explore PAS-blockers to inhibit the generation of PAS-
directed Aβ aggregation.
Figure 36: Potential drug candidates with antioxidant and metal chelating capacity
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CHAPTER VI
Experimental
6.1 Computational Chemistry
This project utilized the advanced structure-based drug design software, Discovery
Studio Client, Accelrys Inc. to investigate compound-enzyme interaction using X-ray crystal
structures for both ChEs obtained from the RCSB Protein Data Bank (PDB: 1B41 (hAChE),
1POI (hBuChE). The Build Fragment tool was utilized to construct ligand molecules and energy
minimized for 1000 iterations reaching a convergence of 0.01 kcal/mol Å. Libdock command
was used for docking experiments in the receptor-ligand interactions protocol of Discovery
Studio and the energy-minimized ligands after defining a 12-15 Å sphere radius within the
enzyme. Docking experiments utilized the Chemistry at HARvard Macromolecular Mechanics
(CHARMM) force field. Ligand-enzyme assembly was then subjected to a molecular dynamics
(MD) simulation using Simulation protocol at a constant temperature of 300 K with a 100 step
equilibration for over 1000 iterations and a time step of 1 fs using a distance dependent dielectric
constant 4r. The optimal binding orientation of the ligand-enzyme assembly obtained after
docking was further minimized for 1000 iterations using the conjugate gradient method until a
convergence of 0.001 kcal/mol Å was reached after which Eintermolecular (kcal/mol) of the
ligand−enzyme assembly was evaluated and the distances measured.
6.2 Chemistry
All solvents and chemical reagents were obtained from various sources (Acros
Organics®, Sigma Aldrich®, Alfa Aesar®, UW Chemstores) with minimum purities of 95% used
as is. The Heidolph Laborta 4000 rotary evaporator was used to evaporate solvent from
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synthesized compounds. Melting points were obtained using the Fisher-Johns apparatus. 1H-
NMR spectra were obtained and analyzed using the Bruker® Avance 300 MHz series
spectrometer with CDCl3 as the solvent. Coupling constants (J values) were recorded with the
values in hertz (Hz). Abbreviations to dictate multiplicity of NMR chemical shifts include: s –
singlet, d – doublet, t – triplet, m – multiplet, br – broad. Mass spectra was obtained from the
JEOL HX110 double focusing mass spectrometer. Purification was accomplished using Merck
230-400 mesh silica gel 60. Compound purity was assessed via thin layer chromatography (TLC)
on Merck 60F254 selica gel plates using different solvent combinations (EtOAc, DCM, 3:1
EtOAc: MeOH). Spots on TLCs are visualized via UV 254 nm. Purity is confirmed with high
pressure liquid chromatography (HPLC) analysis using 0.1 % TFA in water/acetonitrile gradient
by UV detectiion at 254 nm using the Zobrax Eclipse XDB-C8 column 4.6 x 150 mm testing 5
µM of compound showing more than 95% purity. If necessary, further purification is
accomplished via flash chromatography using the same solvent system (Fig. 18).
6.2.1. General Method to Prepare Aminobenzoic Acid Derivatives (4, 5, and 6)
The benzoic acid derivatives were prepared by two different routes: Reaction A and
Reaction b. Reaction a was optimized where tin(II)chloride was used as the reducing agent.
However, Reaction a provided lower yields of desired aminobenzoic acid derivatives. In this
regard, Reaction b, which used Pd/C in presence of hydrazine hydrate provided superior yields of
up to 80%.
Reaction a: 0.01 mol of (1), (2), or (3) is dissolved in excess ethanol (25 mL) at 0⁰C
under argon conditions (Fig. 12). The reaction mixture was reacted with tin-(II)-chloride
dihydrate (0.025 mol) for 60 minutes at room temperature. Ethanol was evaporated under
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reduced pressure and the dried product is re-dissolved in as little EtOAc as possible. The EtOAc
solution was washed 6X with brine solution (Fig. 13). The EtOAc fraction was then dried with
MgSO4 and filtered off. EtOAc is evaporated under reduced pressure to afford the light-yellow
solid product (4, 5, or 6) (23 - 27% yield).
Reaction b: 0.01 mol of (1) is dissolved in ethanol (25 mL) under argon at 0⁰C. Pd/C
(0.001 mol) was added to the reaction mixture followed by the drop-wise addition of hydrazine
hydrate (0.04 mol) (Fig. 14). The reaction mixture was refluxed for 1.5 hours at 80⁰C, cooled
and palladium was filtered off via cotton plug and EtOH was evaporated under reduced pressure.
Upon drying, the product, (4), was obtained as a slightly yellow/brown solid (80% yield). The
analytical data for (4), (5), and (6) are given below.
2-Amino-benzoic acid (4): The product is obtained by reducing (1) with hydrazine hydrate and
Pd/C (1.3 g, 80%). mp: 144 -146°C. 1H-NMR (300 MHz, CDCl3): δ 7.90 (d, J = 8.0 Hz, 1H), δ
7.31 - 7.26 (m, 1H), δ 6.67 - 6.63 (m, 2H)
2-Amino-4-chlorobenzoic acid (5): The product is obtained by reducing (2) with tin-(II)-
chloride (0.39 g, 23%). mp: 205 - 207°C. 1H-NMR (300 MHz, CDCl3): δ 7.80 (d, J = 8.5 Hz,
1H), δ 6.66 (d, J = 2.0 Hz, 1H), δ 6.63 - 6.59 (dd, J = 8.5 Hz, 2.0 Hz, 1H)
2-Amino-5-chlorobenzoic acid (6): The product is obtained by reducing (3) with tin-(II)-
chloride (0.46 g, 27%). mp: 196 - 198°C. 1H-NMR (300 MHz, CDCl3): δ 7.86 (d, J = 2.5 Hz,
1H), δ 7.25 - 7.22 (m, 1H), δ 6.62 (d, J = 9.0 Hz, 1H)
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6.2.2. General method to prepare 6- or 7-substituted-9-chloro-1,2,3,4-tetrahydroacridine
derivatives (7, 8, and 9)
Compound (7, 8, or 9) was synthesized by adding (4, 5, or 6) (0.01 mol) and
cyclohexanone (0.01 mol) in a completely dry reaction vessel at 0⁰C (Fig. 17). This was
followed by the drop-wise addition of phosphorous oxychloride (POCl3) (0.10 mol) and the
solution was allowed to mix for 5 minutes followed by the addition of 3Å molecular sieves. The
reaction mixture is refluxed for 2.5 hours at 120⁰C and then cooled for 20 minutes. The solution
is poured onto ice and 80 mL of 0⁰C water is added. A precipitate was formed and filtered off.
The filtrate is then neutralized with sodium carbonate to precipitate out any remaining product.
The precipitate was collected and dissolved in dichloromethane (DCM) (100 mL). The solution
is then washed five times with equal volume of concentrated sodium bicarbonate solution. The
organic layer is collected and dried with MgSO4 and the solvent is evaporated under reduced
pressure. The crude product was purified by flash chromatography (solvent: DCM) and the
collected fractions were dried under reduced pressure to afford a yellowish solid which was
stored at 4ºC (51 - 82% yield). The analytical data for compounds (7), (8), and (9) are given
below.
9-Chloro-1,2,3,4-tetrahydroacridine (7): The product was obtained by coupling (4) with
cyclohexanone in the presence of POCl3 (4.0 g, 51%) mp: 67 - 69°C 1H-NMR (300 MHz,
CDCl3): δ 8.15 (d, J = 8.0 Hz 1H), δ 7.96 (d, J = 8.5 Hz, 1H), δ 7.66 (t, J = 7.0 Hz, 1H), δ 7.61 (t,
J = 7.0 Hz, 1H), δ 3.22 - 3.11 (m, 2H), δ 3.05 - 2.99 (m, 2H)
6,9-Dichloro-1,2,3,4-tetrahydroacridine (8): The product was obtained by coupling (5) with
cyclohexanone in the presence of POCl3 (6.0 g, 82%). mp: 83 - 85°C. 1H-NMR (300 MHz,
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CDCl3): δ 8.94 (s, 1H), δ 7.99 (s, 1H), δ 7.47 (dd, J = 9 Hz, 2 Hz, 1H), δ 3.11 - 3.09 (m. 2H), δ
3.01 - 2.99 (m, 2H), δ 1.97-1.88 (m, 4H)
7,9-Dichloro-1,2,3,4-tetrahydroacridine (9): The product was obtained by coupling (6) with
cyclohexanone in the presence of POCl3 (5.5 g, 75%). mp: 79 - 81°C 1H-NMR (300 MHz,
CDCl3): δ 8.11 (d, J = 2.0 Hz, 1H), δ 7.88 (d, J = 9.0 Hz, 1H), δ 7.56 (dd, J = 9.0 Hz, 2.0 Hz,
1H), δ 3.08-3.06 (m, 2H), δ 3.00 - 2.87 (m, 2H), δ 1.96 - 1.88 (m, 4H)
6.2.3. General method to prepare 6- or 7-substituted-N-benzyl-1,2,3,4-tetrahydroacridine-
9-amine derivatives (10a-d, 11a-e, 12a-e, 13a-f)
Coupling the various benzylamine groups to (7, 8, or 9) was done in two ways. i) Firstly,
sodium iodide (0.0006 mol) was added to (7, 8, or 9) (0.002 mol), and dissolved as much as
possible in excess butanol (5 mL) (Fig. 19). Benzylamine (0.005 mol) was added and the reaction
mixture was refluxed at 150ºC for 4.5 hours, cooled, and then immediately dried under reduced
pressure. It was re-dissolved in excess DCM and washed three times with concentrated brine
solution. The organic layer was dried with MgSO4 and the solvent was evaporated under reduced
pressure. The remaining product was purified via flash chromatography (solvent: EtOAc). Some
compounds were purified by repetitive flash chromatography (2-3 repeats).
ii) Sodium iodide (0.6 mmol) was added to (7), (8), or (9) (0.002 mol), followed by the
addition of benzylamines (0.005 mol) (Fig. 19). Phenol (0.01 mol) was added and the reaction
mixture was refluxed at 180ºC for 3 hours. The reaction mixture was allowed to cool to room
temperature, dissolved in excess DCM, then washed three times with concentrated brine
solution. The organic layer was collected and dried with MgSO4 and the solvent was evaporated
under reduced pressure. The remaining product was purified via flash chromatography (solvent:
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EtOAc). Some compounds were purified by repetitive flash chromatography (2-3 repeats). The
analytical data for compounds 10a-d, 11a-e, 12a-e, 13a-f are shown below.
6.2.3.1 Analytical Data for Benzylamine and Substituted-Benzylamine Series
N-1,2,3,4-tetrahydroacridin-9-amine (10a): The product was obtained by coupling (7) with
benzylamine (0.45 g, 45%). mp:111-113 ºC. 1H-NMR (300 MHz, CDCl3): δ 7.90 (t, J = 8.0 Hz,
2H), δ 7.49 (t, J = 8.0 Hz, 1H), δ 7.35 – 7.25 (m, 6H), δ 4.56 (d, J = 6.0 Hz, 2H), δ 4.17 (br s,
1H), δ 3.02 (t, J = 6.0 Hz, 2H), δ 2.57 (t, J = 6.0 Hz, 2H), δ 1.86 – 1.78 (m, 4H). ESI-MS: 289
[M+H]+
N-(2-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (10b): The product was obtained by
coupling (7) with 2-methoxybenzylamine (0.45 g, 40%). mp: semisolid. 1H-NMR (300 MHz,
CDCl3): δ 8.47 (d, J = 8.5 Hz, 1H), δ (d, J = 8.5 Hz, 1H), δ 7.52 (t, J = 8.0 Hz, 1H), δ 7.33 - 7.22
(m, 3H), δ 6.89 – 6.78 (m, 2H), δ 6.11 (br s, 1H), δ 4.88 (s, 2H), δ 3.76 (s, 3H), δ 3.18 – 3.08 (m,
2H), δ 2.61 – 2.56 (m, 2H), 1.87 – 1.76 (m, 4H). ESI-MS: 319 [M+H]+
N-(3-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (10c): The product was obtained by
coupling (7) with 3-methoxybenzylamine (0.35 g, 32%). mp: semisolid. 1H-NMR (300 MHz,
CDCl3): δ 7.90 (t, J = 8.0 Hz, 2H), δ 7.52 (t, J = 8.0 Hz, 1H), δ 7.35-7.23 (m, 2H), δ 6.92-6.81
(m, 3H), δ 4.56 (d, J = 6.0 Hz, 2H), δ 4.21-4.17 (m, 1H), δ 3.75 (s, 3H), δ 3.04 (t, J = 6.0 Hz,
2H), δ 2.16 (t, J = 6.0 Hz, 2H), δ 1.92-1.81 (m, 4H). ESI-MS: 319 [M+H]+
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N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (10d): The product was obtained
by coupling (7) with 3,4-dimethoxybenzylamine (0.40 g, 41%). mp: semisolid. 1H-NMR (300
MHz, CDCl3): δ 7.94 (d, J = 8.5 Hz, 1H), δ 7.90 (d, J = 8.5 Hz, 1H), δ 7.52 (t, J = 8.0 Hz, 1H), δ
7.30 (t, J = 7.5 Hz, 1H), δ 6.81 (q, J = 8.0 Hz, 2H), δ 6.76 (s, 1H), δ 4.55 – 4.52 (m, 2H), δ 4.13
(br s, 1H), δ 3.86 (s, 3H), δ 3.78 (s, 3H), δ 3.02 (t, J = 6.0 Hz, 2H), δ 2.60 (t, J = 5.0 Hz, 2H), δ
1.86 – 1.80 (m, 4H). ESI-MS: 349 [M+H]+
N-Benzyl-6-Chloro-1,2,3,4-tetrahydroacridin-9-amine (11a): The product was obtained by
coupling (8) with benzylamine (0.40 g, 41%). mp: semisolid. 1H-NMR (300 MHz, CDCl3): δ
8.01 - 7.94 (m, 1H), δ 7.89 (d, J = 9.0 Hz, 1H), δ 7.38 – 7.29 (m, 6H), δ 4.63 (s, 2H), δ 4.27 (br s,
1H), δ 3.09 – 3.00 (m, 2H), 2.60 – 2.54 (m, 2H), 1.91 – 1.79 (m, 4H). ESI-MS: 323 [M+H]+
6-Chloro-N-(2-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (11b): The product was
obtained by coupling (8) with 2-methoxybenzylamine (0.25 g, 25%). mp: semisolid. 1H-NMR
(300 MHz, CDCl3): δ 7.91 (d, J = 8.0 Hz, 2H), δ 7.27 (s, 1H), δ 7.15 (d, J = 7.0 Hz, 1H), δ 6.87
(d, J = 7.0 Hz, 2H), δ 5.27 (s, 1H), δ 4.56 (s, 2H), δ 3.80 (s, 3H), δ 3.02 – 3.00 (m, 2H), δ 2.58 –
2.59 (m, 2H), δ 1.85 – 1.82 (m, 4H). ESI-MS: 353 [M+H]+
6-Chloro-N-(3-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (11c): The product was
obtained by coupling (8) with 3-methoxybenzylamine (0.15 g, 15%). mp: semisolid. 1H-NMR
(300 MHz, CDCl3): δ 7.92 (s, 1H), δ 7.87 (d, J = 9.0 Hz, 1H), δ 7.30 – 7.26 (m, 2H), δ 6.90 –
6.84 (m, 3H), δ 4.57 (s, 2H), δ 4.19 (br s, 1H), δ 4.19 (br s, 1H), δ 3.77 (s, 3H), δ 3.01 (t, J = 6.0
Hz, 2H), δ 2.57 (t, J = 6.0 Hz, 2H), δ 1.87 – 1.85 (m, 4H). ESI-MS: 353 [M+H]+
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6-Chloro-N-(4-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (11d): The product was
obtained by coupling (8) with 4-methoxybenzylamine (0.14 g, 14%). mp: semisolid. 1H-NMR
(300 MHz, CDCl3): δ 7.95 – 7.89 (m, 2H), δ 7.27 – 7.19 (m, 3H), δ 6.85 (d, J = 5 Hz, 2H), δ 4.59
- 4.51 (m, 1H), δ 4.29 (br s, 1H), δ 3.80 (s, 3H), δ 3.10 – 2.99 (m, 2H), δ 2.58 – 2.54 (m 2H),
1.89 – 1.83 (m, 4H). ESI-MS: 353 [M+H]+
6-Chloro-N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (11e): The product
was obtained by coupling (8) with 3,4-dimethoxybenzylamine (0.40 g, 35%) . mp: 131-133 ºC.
1H-NMR (300 MHz, CDCl3): δ 7.90 – 7.87 (m, 2H), δ 7.27 – 7.24 (m, 1H), δ 6.87 – 6.81 (m,
2H), δ 6.75 (s, 1H), δ 4.53 (s, 2H), δ 4.13 (br s, 1H), δ 3.87 (s, 3H), δ 3.79 (s, 3H), δ 3.00 (t, J =
6.0 Hz, 2H), δ 2.55 (t, J = 5.0 Hz, 2H), δ 1.87 – 1.75 (m, 4H). ESI-MS: 383 [M+H]+
N-Benzyl-7-Chloro-1,2,3,4-tetrahydroacridin-9-amine (12a): The product was obtained by
coupling (9) with benzylamine (0.35 g, 36%). mp: semisolid. 1H-NMR (300 MHz, CDCl3): δ
8.54 (d, J = 9.0 Hz, 1H), δ 8.17 (s, 1H), δ 7.59 (dd, J = 9.0 Hz, 2 Hz, 1H), δ 7.44-7.25 (m, 5H), δ
5.91(br s, 1H), δ 5.06 (s, 2H), δ 3.29 (t, J = 6.0 Hz, 2H), δ 2.59 (t, J = 6 Hz, 2H), δ 1.90-1.87 (m,
4H). ESI-MS: 323 [M+H]+
7-Chloro-N-(2-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (12b): The product was
obtained by coupling (9) with 2-methoxybenzylamine (0.12 g, 12%). mp: semisolid. 1H-NMR
(300 MHz, CDCl3): δ 8.00 (d, J = 2.0 Hz, 1H), δ 7.79 (d, J = 6.0 Hz, 1H), δ 7.42 (dd, J = 9.0 Hz,
2.0 Hz, 1H), δ 7.20 (t, J = 7.0 Hz, 1H), δ 7.10 (d, J = 5.0 Hz, 1H), δ 6.81 (t, J = 5.0 Hz, 2H), δ
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4.46 (s, 2H), δ 4.38 (br s, 1H), δ 3.81 (s, 3H), δ 2.97 (t, J = 6.0 Hz, 3H), δ 2.58 (t, J = 6.0 Hz,
2H), δ 1.85-1.78 (m, 4H). ESI-MS: 353 [M+H]+
7-Chloro-N-(3-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (12c): The product was
obtained by coupling (9) with 3-methoxybenzylamine (0.17 g, 17%). mp: semisolid. 1H-NMR
(300 MHz, CDCl3): δ 7.94 - 7.93 (m, 1H), δ 7.81 (d, J = 9.0 Hz, 1H), δ 7.43 (dd, J = 9.0 Hz, 2.0
Hz, 1H), δ 7.27-7.22 (m, 1H), δ 6.88-6.81 (m, 3H), 4.51 (d, J = 6.0 Hz, 2H), δ 4.11 (br s, 1H), δ
3,74 (s, 3H), δ 2.99 (t, J = 6.0 Hz, 2H), δ 2.55 (t, J = 6.0 Hz, 2H), δ 1.84-1.81 (m, 4H). ESI-MS:
353 [M+H]+
7-Chloro-N-(4-methoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (12d): The product was
obtained by coupling (9) with 4-methoxybenzylamine (0.20 g, 20%). mp: semisolid. 1H-NMR
(300 MHz, CDCl3): δ 7.96 (s, 1H), δ 7.83 (d, J = 9.0 Hz, 1H), δ 7.50-7.46 (m, 1H), δ 7.19 (d, J =
8.0 Hz, 2H), δ 6.86 (d, J = 8.0 Hz, 2H), δ 4.51 (s, 2H), δ 4.03 (br s, 1H), δ 3.80 (s, 3H), δ 3.00 (t,
J = 6.0 Hz, 2H), δ 2.54 (t, J = 6.0 Hz, 2H), 1.85-1.82 (m, 4H). ESI-MS: 353 [M+H]+
7-Chloro-N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine (12e): The product
was obtained by coupling (9) with 3,4-dimethoxybenzylamine (0.23 g, 20%). mp: 113-115 ºC.
1H-NMR (300 MHz, CDCl3): δ 7.96 (d, J = 2.0 Hz, 1H), δ 7.82 (d, J = 9.0 Hz, 1H), δ 7.46 (dd, J
= 9.0 Hz, 2 Hz, 1H), δ 6.81 - 6.87 (m, 2H), δ 6.75 (s, 1H), δ 4.50 (d, J = 3.5 Hz, 2H), δ 4.09 (br s,
1H), δ 3.87 (s, 3H), δ 3.80 (s, 3H), δ 2.99 (t, J = 6.0 Hz, 2H), δ 2.56 (t, J = 6.0 Hz, 2H), δ 1.87-
1.83 (m, 4H). ESI-MS: 383 [M+H]+
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6.2.3.2 Analytical Data for N-(pyridinylmethyl)-1,2,3,4-tetrahydroacridin-9-amine
Derivatives
N-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine (13a): The product was obtained
by coupling (7) with 2-picolylamine (0.35 g, 35%). mp: 103-105 ºC 1H-NMR (300 MHz,
CDCl3): δ 8.64 (d, J = 4.5 Hz, 1H), δ 8.09 (d, J = 8.0 Hz, 1H), δ 7.89 (d, J = 8.0 Hz, 1H), δ 7.60
(td, J = 8.0 Hz, 2.0 Hz, 1H), δ 7.51 (td, J = 8.0 Hz, 1.0 Hz, 1H), δ 7.33 (t, J = 7.5 Hz, 1H), δ 7.17
– 7.21 (m, 2H), 5.86 (br s, 1H), δ 4.76 (d, J = 5.0 Hz, 2H), δ 3.00 – 3.10 (m, 2H), δ 2.90 – 2.80
(m, 2H), δ 1.92 – 1.87 (m, 4H). ESI-MS: 290 [M+H]+
N-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine (13b): The product was obtained
by coupling (7) with 3-picolylamine (0.40 g, 40%). mp: semisolid. 1H-NMR (300 MHz, CDCl3):
δ 8.60 (d, J = 2.0 Hz, 1H), δ 8.53 (dd, J = 5.0 Hz, 1.5 Hz, 1H), δ 7.89 (dd, J = 8.0 Hz, 6.0 Hz,
2H), δ 7.62 – 7.53 (m, 2H), δ 7.32 (t, J = 7.0 Hz, 1H), δ 7.27 – 7.23 (m, 1H), δ 4.57 (d, J = 7.0
Hz, 2H), δ 4.07 – 4.11 (m, 1H), δ 3.03 (t, J = 6.0 Hz, 2H), δ 2.61 (t, J = 6.0 Hz, 2H), δ 1.89 –
1.83 (m, 4H). ESI-MS: 290 [M+H]+
6-Chloro-N-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine (13c): The product was
obtained by coupling (8) with 2-picolylamine (0.35 g, 36%). mp: 117 – 119 ºC. 1H-NMR (300
MHz, CDCl3): δ 8.65 (d, J = 5.0 Hz, 1H), δ 8.08 (d, J = 6.0 Hz, 1H), δ 7.99 (s, 1H), δ 7.66 (t, J =
3.0 Hz, 1H), δ 7.29 (dd, J = 9.0 Hz, 2.0 Hz, 1H), δ 7.28-7.23 (m, 2H), δ 6.43 (br s, 1H), δ 4.86
(d, J = 5.0 Hz, 2H), δ 3.08-3.05 (m, 2H), δ 2.82 - 2.79 (m, 2H), δ 1.92-1.90 (m, 4H). ESI-MS:
324 [M+H]+
6-Chloro-N-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine (13d): The product was
obtained by coupling (8) with 3-picolylamine (0.25 g, 26%). mp: 87 – 89 ºC 1H-NMR (300
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MHz, CDCl3): δ 8.59 (d, J = 2.0 Hz, 1H), δ 8.55 (dd, J = 5.0 Hz, 1 Hz, 1H), δ 7.93 (d, J = 2.0
Hz, 1H), δ 7.84 (d, J = 9.0 Hz, 1H), δ 7.58 (d, J = 8.0 Hz, 1H), δ 7.26 (dd, J = 9.0 Hz, 2 Hz, 2H),
δ 4.60 (d, J = 6.5 Hz, 2H), δ 4.25 (br s, 1H), δ 3.01 (t, J = 6.0 Hz, 2H), δ 2.57 (t, J = 6.0 Hz, 2H),
δ 1.91 – 1.89 (m, 4H). ESI-MS: 324 [M+H]+
7-Chloro-N-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine (13e): The product was
obtained by coupling (9) with 2-picolylamine (0.45 g, 47%). mp: semisolid. 1H-NMR (300
MHz, CDCl3): δ 8.66 – 8.63 (m, 1H), δ 8.10 (d, J = 2 Hz, 1H), δ 7.83 (d, J = 7.5 Hz, 1H), δ 7.68
– 7.62 (m, 1H), δ 7.46 (dd, J = 9.0 Hz, 2 Hz, 1H), δ 7.24 - 7.19 (m, 2H), δ 6.05 (br s, 1H), δ 4.79
– 4.73 (m, 2H), δ 3.10 – 2.99 (m, 2H), δ 2.85 – 2.75 (m, 2H), δ 1.93 – 1.81 (m, 4H). ESI-MS:
324 [M+H]+
7-Chloro-N-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine (13f): The product was
obtained by coupling (9) with 3-picolylamine (0.26 g, 27%). mp: 126 – 128 ºC 1H-NMR (300
MHz, CDCl3): δ 8.59 (d, J = 2.0 Hz, 1 H), δ 8.55 (dd, J = 5.0 Hz, 1.5 Hz, 1H), δ 7.90 – 7.93 (m,
2 H), δ 7.59 (d, J = 8.0 Hz, 1H), δ 7.48 (dd, J = 9.0 Hz, 2.0 Hz, 1H), δ 7.25 (dd, J = 8.0 Hz, 5.0
Hz, 2H), δ 4.60 (d, J = 6.5 Hz, 2H), δ 4.24 (br s, 1H), δ 3.03 (t, J = 6.0 Hz, 2H), δ 2.57 (t, J = 6.0
Hz, 2H), δ 1.87 – 1.84 (m, 4H). ESI-MS: 324 [M+H]+
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6.3 Biological Evaluation
6.3.1 Cholinesterase Inhibition Evaluation
Test compounds were evaluated for their ability to inhibit hAChE and hBuChE using a
96-well plate (Fig. 37). Reference compounds tacrine, galantamine, and donepezil were used for
comparison. Test compound solutions were solubilized in minimum amount of DMSO (1% v/v)
and a wide range of concentrations were used (0.025 – 25 µM) to determine the IC50 values.
Each well, with the exception of blanks, and controls, contained 160 µL of DTNB, 50 µL
hAChE or hBuChE solution, and 10 µL of test compound. Blank wells contained 160 µl DTNB,
50 µL buffer A, and 10 µL DMSO. 100% ChE activity (100% activity) contained 160 µl DTNB,
50 µL hAChE/hBuChE, 8 µl buffer A, and 2 µL DMSO. Aluminum foil was used to cover the
96-well plate from light exposure due to DTNB light-sensitivity. A 5 minute incubation period at
room temperature was followed, and 30 µL of substrate (acetylthiocholine iodide 15 mM or
butyrylthiocholine iodide 15 mM) (final volume 250 µL) was then added. The absorbance values
were taken every minute for 5 minutes at 410 nm. The average absorbance value from all 6
readings (t = 0, 1, 2, 3, 4, 5 min) were subtracted from average absorbance values from the 100%
activity controls, then divided by the average absorbance of 100% activity control. The percent
inhibition was obtained as per the equation below. The IC50 values for each compound were
calculated by plotting their percent inhibition values against their respective concentrations on a
logarithmic scale. A line of best fit was determined and the IC50 is calculated from the equation.
Percent inhibition =
(100%-activity absorbance – test compound absorbance)/(100%-activity absorbance) x 100
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Figure 37: General set-up of 96-well plate. Red: test compounds with hAChE; Pink: 100%
hAChE activity; Dark Blue: test compounds with hBuChE; Light Blue: 100% hBuChE activity;
Yellow: blanks without ChE or test compound; White: empty wells
6.3.1.1 Solutions and Substrates
Buffer A was prepared by dissolving 3.029 g of Trizma base (Sigma), 2.922 g of NaCl
and 2.033 g of MgCl2•6H2O in 450 mL of UPW. 1M HCl was added to the solution until pH 8.0,
and finally the solution was filled up to 500 mL with ultra pure water (UPW).
Buffer B was prepared by dissolving 3.029 g of Trizma base (Sigma) in UPW followed
by 0.50 g of BSA and 20 mL of UPW. Finally, 0.086 mL of 1M HCl was added with the final
solution pH at 8.0. Then the volume was made up to 50 mL with UPW.
Acetylcholinesterase solution (0.22 units/mL) was prepared by dissolving the supplied
amount of hAChE (425.95 units/mg) in 9.4 mL of buffer B. 0.5 mL of the aforementioned
solution was added to an additional 0.5 mL of buffer B; 0.011 mL of this solution was added to
5.31 mL of buffer B yielding a final concentration of 0.22 units/mL.
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Butyrylcholinesterase solution (0.12 units/mL) was prepared by dissolving the supplied amount
of hBuChE (221 units/mg) in 9.0 mL of buffer B. 0.5 mL of the aforementioned solution was
added to an additional 0.5 mL of buffer B; 0.010 mL of this solution was added to 9.198 mL of
buffer B yielding a final concentration of 0.12 units/mL.
6.3.2 Antioxidant Capacity Evaluation
In a 96-well plate, 50 µL of test compound was first added followed by 200 µL of DPPH (ATest;
final volume 250 µL). Blank controls are comprised of 50 µL test compound solution and 200
µL MeOH (ATest Blank; final volume 250 µL) and carried out in duplicate for each test compound
concentration. DPPH control wells include 50 µL MeOH and 200 µL DPPH solution (ADPPH;
final volume 250 µL). Negative controls contain 250 µL of MeOH, and empty well controls are
left without any solutions (final volume 250 µL). Reference compound trolox or curcumin were
included. The plate was incubated at room temperature while shaking for 30 minutes.
Absorbance values were taken at time 0 and 30 minutes (517 nm). The percent inhibition was
calculated as per the equation below:
Percent inhibition = [(ADPPH – (ATest – ATest Blank))/ADPPH] x 100
6.3.2.1 Preparation of DPPH solution
DPPH solution was prepared by dissolving 5 µmol of DPPH in 40 mL of MeOH (125
µM). Dilute the solution to 62.5 µM with MeOH to finalize the DPPH solution used in test
compound evaluation. The solution was stored to protect it from light exposure.
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6.3.3 Chelation Capacity Evaluation
Iron chelation capacity: Stock solutions of test compounds were prepared in tris buffer
(pH 7.4; 100 mM). Test compound solution (95 µL: final concentration 50 µM) was added to
FeSO4 • 7H2O (10 µL: final concentration 40 µM) followed by ferrozine (95 µL: final
concentration 100 µM) (ATest; final volume 200 µL). The absorbance value of the mixture was
recorded at 562 nm after incubating at room temperature for 20 minutes. Test compound blanks
were prepared with test compound solution (95 µL) added to FeSO4 • 7H2O (10 µL: final
concentration 40 µM), and 95 µL UPW instead of ferrozine. Results were compared with
reference agents clioquinol and desferoxamine. The percentage of iron bound was then
determined. The percent of chelation were calculated following the equation:69
Chelating ability % = [1 – absorbance sample/absorbance control] x 100
6.3.3.1 Preparation of Reagent and Buffer solutions
Tris buffer was prepared by dissolving 3.0 g (0.025 mol)
tris(hydroxymethyl)aminomethane) in 200 mL of UPW in a volumetric flask. The pH was
adjusted to 7.4 through drop-wise addition of HCl solution (1M). The volume was made up to
250 mL
Ferrozine stock solution (10 mM) was prepared by weighing 4.92 mg of 3-(2-pyridyl)-
5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate (ferrozine) in 1 mL tris
buffer solution. This solution was diluted to 210 µM using tris buffer.
Iron stock solution (10 mM) was prepared by dissolving 2.78 mg iron(II)sulphate
heptahydrate in 1 mL MeOH. This solution was diluted to to 800 µM and used to evaluate
chelation.
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6.3.4 Evaluation of Cell Viability
Evaluation of cell viability was performed using the SH-SY5Y neuroblastoma cell line
via examination of the reduction of 3(4,5 dimethylthiazol-2-yl)-2.5 diphenyltetrazolium bromide
(MTT) into a purple formazan via mitochondrial reductase activity. Cells were plated at a density
of 4  105 cells/mL in growth media consisting of 1:1 DMEM and Ham’s F12 (Thermo, Fisher),
supplemented with 2.5 mM glutamate and 10% fetal bovine serum at 37ºC in 5% CO2. Cells
were incubated after treated with test compounds, 50 µM and 25 µM, for 24 hours at 37ºC (n =
3). After incubation, each well was treated with MTT solution equal to 10% of the cell culture
medium volume followed by an additional 3 hour incubation period at 37ºC in 5% CO2. Upon
incubation completion the generated formazan was solubilized with MTT reagent solution (10%
Triton X-100 and 0.1 N HCl in anhydrous isopropanol) in equal volume to the culture medium
for each well with readings done at 570 nm with subtraction of background absorbance values.
.
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